Sign In
Buy CRMD
$8.23
+0.0600 (+0.734%)
At Close: Jun 03, 2026
Allspring Global Investments Holdings LLC Makes New Investment in CorMedix Inc $CRMD
03:51am, Monday, 27'th Oct 2025
Allspring Global Investments Holdings LLC bought a new stake in shares of CorMedix Inc (NASDAQ: CRMD) in the undefined quarter, according to the company in its most recent filing with the SEC. The fun
CorMedix: Strong Buy After Strong Developments And A Strategy Before Earnings
11:29pm, Thursday, 23'rd Oct 2025
CorMedix's acquisition of Melinta Therapeutics diversifies its portfolio, boosting 2025 revenue guidance to at least $375M and reducing single-product risk. DefenCath remains the primary revenue drive
CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath
08:30am, Thursday, 23'rd Oct 2025
BERKELEY HEIGHTS, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening
Halper Sadeh LLC Encourages CorMedix Inc. Shareholders to Contact the Firm to Discuss Their Rights
04:05pm, Wednesday, 22'nd Oct 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of CorMedix Inc. (NASDAQ: CRMD) breached their fiduciary duties to sha
Earnings Estimates Rising for CorMedix (CRMD): Will It Gain?
01:20pm, Tuesday, 21'st Oct 2025
CorMedix (CRMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Analysts See a 68.59% Upside in CorMedix (CRMD): Can the Stock Really Move This High?
10:56am, Tuesday, 21'st Oct 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 68.6% in CorMedix (CRMD). While the effectiveness of this highly sought-after metric is questionable, the posit
CorMedix (CRMD) Surges 19.5%: Is This an Indication of Further Gains?
10:16am, Tuesday, 21'st Oct 2025
CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results?
11:11am, Monday, 20'th Oct 2025
CorMedix's DefenCath, the first FDA-approved antimicrobial catheter lock, is expected to drive Q3 growth as new Melinta drugs add to momentum.
CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance
07:30am, Monday, 20'th Oct 2025
‒ Q3 2025 Unaudited Pro Forma Net Revenue of more than $125 million ‒ ‒ Q3 2025 Unaudited DefenCath Net Revenue of more than $85 million ‒ ‒ Raising FY 2025 Pro Forma Net Revenue Guidance to
CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?
11:41am, Tuesday, 14'th Oct 2025
CRMD shares slip 16%, but rising DefenCath sales and the Melinta deal can set the stage for renewed growth.
Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In?
11:36am, Tuesday, 07'th Oct 2025
CRMD's DefenCath gives the company a first-mover edge in CRBSI prevention, but looming heparin giants test how long its lead can last.
CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO
08:30am, Monday, 29'th Sep 2025
- Enrollment Completed in Ongoing Phase III ReSPECT Study in Prophylaxis of Fungal Infections in Adult Patients Undergoing Allogeneic Blood and Marrow Transplant -
CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?
11:45am, Tuesday, 23'rd Sep 2025
CorMedix and Mirum Pharmaceuticals are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.
CorMedix: Strong Adoption Curve And Policy Environment
04:46am, Monday, 22'nd Sep 2025
CorMedix is commercializing DefenCath, the only FDA-approved antimicrobial catheter-lock solution, with strong clinical results and rapid adoption in dialysis clinics. Medicare's TDAPA policy ensures
Can CorMedix's Melinta Deal Fuel Growth Via Portfolio Diversification?
11:56am, Thursday, 18'th Sep 2025
CRMD's $300M Melinta buy adds seven therapies, easing reliance on DefenCath sales and bolstering growth in hospital-focused markets.
